{"analyses":[{"ciLowerLimit":"-0.285","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.466","groupDescription":"Proteinuria (g/24 hours), baseline versus end study levels.","groupIds":["OG000"],"nonInferiorityComment":"P-values and confidence intervals are not adjusted for multiple testing","nonInferiorityType":"OTHER","pValue":"0.603","paramType":"Change in outcome measure","paramValue":"0.091","statisticalComment":"degrees of freedom = 10","statisticalMethod":"Mixed Models Analysis"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.85","value":"5.91"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"}],"units":"Participants"}],"description":"Patients with predominant amyloid kidney involvement at enrollment.","dispersionType":"Standard Deviation","groups":[{"description":"Patients with predominant amyloid kidney involvement at enrollment.","id":"OG000","title":"Amyloid Nephropathy: Proteinuria (g/Day)"}],"paramType":"MEAN","populationDescription":"Analysis is limited to the patients with predominant amyloid kidney involvement at enrollment. Mixed models analyses of change from baseline levels of creatinine clearance (ml/min) and proteinuria (g/day) were performed to include all data collected at baseline, 6 and 12 months.","reportingStatus":"POSTED","timeFrame":"Data were assessed at baseline, 6 and 12 months, with change at end of study reported","title":"Amyloid Nephropathy: Proteinuria","type":"PRIMARY","unitOfMeasure":"g/day"}